Pfizer now hopes to inform U.S. regulators of the effectiveness of its COVID-19 vaccine in children in late May or early June.
Pfizer is testing three very small doses of the vaccine in children under 5 years of age after the strength of two injections was insufficient. Preliminary results were expected last month, but the company announced the latest deadlines in Tuesday’s quarterly review. Financial consequences.
Currently in the United States, only children over the age of 5 can be vaccinated with the Pfizer vaccine: 18 million young children remain unprotected.
Opponent Moderna expects to be the first to offer vaccinations to younger children. Last week, he archived data from the Food and Drug Administration, hoping his two low-dose vaccinations would work on children under 5 years old. Moderna has also filed applications with the FDA for older children, though the agency has not made a decision on the matter.
The FDA has already identified the June Events estimate to publicly review data on COVID-19 vaccines for children under 5 years of age, from one or both companies.
The Associated Press Department of Health and Science receives support from the Science Education Department of the Howard Hughes Medical Institute. AP is solely responsible for all content.
Source: Huffpost
